Skip to content
Open access

Fatty Acid Oxidation Disorders Detected by Newborn Screening: Clinical, Biochemical and Genetic Spectrum in a Single‐Center Cohort

Oct 2026 · JIMD Reports · Vol 67 · 0 citations · 36 references
Medicine

TL;DR

Current biochemical markers are useful for early risk stratification but remain insufficient to predict long‐term clinical severity, and these findings support individualized multidisciplinary follow‐up, including specialized nutritional care and systematic neuropsychological assessment.

Abstract

ABSTRACT Newborn screening (NBS) has significantly improved early detection and survival in fatty acid oxidation disorders (FAODs). However, the expanding phenotypic spectrum challenges prognostic stratification, and long‐term morbidity remains incompletely characterized. We conducted an observational, retrospective, single‐center study of patients with FAODs identified through NBS and followed between 2011 and 2024. Clinical, biochemical, genetic, and nutritional data were extracted from medical records. Correlations between biochemical markers, enzymatic activity, and clinical outcomes were analyzed. The study was approved by the Research Committee of the Instituto de Investigación, Hospital 12 de Octubre (Madrid). Sixty‐five patients were included: 42 MCADD, 11 VLCADD, 5 LCHADD, 2 CPT1D, 3 CPT2D, 1 CACTD, and 1 MADD. Median age at last follow‐up was 7.2 years (range 0.4–13.6). Two patients died during follow‐up (overall mortality 3.1%). In MCADD, confirmatory C8 concentrations correlated with residual enzyme activity and metabolic decompensations. In VLCADD, NBS and confirmatory C14:1 levels correlated with enzyme activity but not with clinical severity. VLCADD showed marked clinical heterogeneity, whereas LCHADD patients had the highest disease burden and required the most intensive nutritional management. Overall, 40% of patients experienced at least one metabolic decompensation, occurring significantly more frequently in LC‐FAOD than in MCADD. Neuropsychological manifestations were observed in 16.9% of patients. In summary, NBS markedly improves survival in FAODs, but morbidity remains substantial, particularly in LC‐FAOD. Current biochemical markers are useful for early risk stratification but remain insufficient to predict long‐term clinical severity. These findings support individualized multidisciplinary follow‐up, including specialized nutritional care and systematic neuropsychological assessment.

Read PDF

Similar papers

Open access Oct 2026

A Decade of Neonatal Inherited Metabolic Disorder Screening Experience in Ningbo, China: Screening Performance, Disease Spectrum, and Genetic Characteristics

Expanded newborn screening (NBS) using tandem mass spectrometry (MS/MS) can identify multiple inborn errors of metabolism (IEMs), but regional disease and genetic spectra vary. We retrospectively analyzed 611,080 newborns screened at the Women and Children’s Hospital of Ningbo University from July 2014 to December 2024...

Fei Wang, Xiang-Chun Yang, Dan-Yan Zhuang et al. · 0 citations
Open access Sep 2026

Disorders of vitamin B9 and B12 metabolism in children: prevalence, selected clinical aspects, and optimization of diagnostic approaches

Disorders of vitamin B9 and B12 metabolism is an important problem in modern pediatrics due to its prevalence, nonspecific clinical manifestations, and diagnostic difficulties. Aim – to evaluate the prevalence and features of vitamin B9 and B12 metabolic disorders in school-aged children, to assess the role of hyper­ho...

I. Lembryk, T. Shatynska, H. Dutchak et al. · 0 citations
Review Open access Nov 2026

P-409: Epidemiological profile and diagnostic presentation of type 1 diabetes mellitus in a tertiary center in Brazil

Type 1 diabetes mellitus(T1DM) is an endocrine disorder that impairs glucose metabolism. Diagnosis typically occurs during childhood, and may be established through laboratory abnormalities in asymptomatic patients, classic symptoms (polyuria, polydipsia, and weight loss) or diabetic ketoacidosis(DKA). To...

C. Andrade Coutinho, G. Carvalho Pinho, A. C. Lins Neves et al. · 0 citations
Open access Oct 2026

Clinical and genetic spectrum in a cohort of patients with suspected mitochondrial disease

The findings highlight the genetic and clinical heterogeneity of MDs, emphasizing the importance of integrating molecular, biochemical, and neuroimaging data to enhance early diagnosis and facilitate personalized treatment strategies.

Doina Secu, Daniela Blanita, N. Usurelu et al. · 0 citations
Open access Oct 2026

Metabolic Dysfunction‐Associated Steatotic Disease and Genetic Risk in Germany—An Observational Real‐World Cohort Study

ABSTRACT Background Metabolic dysfunction‐associated steatotic disease (MASLD) affects increasing numbers of patients worldwide. The PNPLA3 p.I148M variant represents a major genetic determinant of MASLD progression. The loss‐of‐function HSD17B13 polymorphism rs72613567 was reported in turn to be hepatoprotective. Pati...

Marcin Krawczyk, F. Grünhage, L. Schubert et al. · 0 citations
Open access Sep 2026

A STUDENT PERSPECTIVE: NEWBORN SCREENING FOR INBORN ERROR OF METABOLISM- CASE STUDY OF METHYLMALONIC ACIDURIA (MMA) USING URINARY GCMS ANALYSIS

Methylmalonic acidemia (MMA) is a rare autosomal recessive inborn error of metabolism (IEM) caused by defects in Methylmalonyl-CoA mutase activity or cobalamin (Vitamin B12) metabolism, leading to the accumulation of toxic organic acids, mainly increased MMA in blood & urine. Early diagnosis is critical as untreated MM...

Shruti Sharma, U. Khan, U. Dave · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.